On January 2020, the discovery of a new coronavirus (SARS-CoV-2) was officially announced by the Chinese health authorities and the World Health Organization (WHO). Its complete genome was sequenced by the laboratory of respiratory infection viruses at the Institut Pasteur on 29 January 2020 in France. This will allow the identification of antigenic structures involved in the immune response and the development of serological diagnostic tests. Many questions are being asked about this new virus and the infection it causes, including questions about the percentage of asymptomatic and pauci-symptomatic forms. Serological studies can provide answers to these questions. There is no serological test for SARS-COV-2 yet, but the laboratory of respiratory infection viruses at the Institut Pasteur is working on its development. This study proposes to carry out a collection of samples taken from subjects who travelled to China before the epidemic outbreak or suspected of being infected with SARS-CoV-2. As soon as it is available, serology will be performed on the collected samples.
On January 2020, the discovery of a new coronavirus (SARS-CoV-2) was officially announced by
the Chinese health authorities and the World Health Organization (WHO). This new virus is
presented as the causative agent of pneumonias. Its complete genome was sequenced by the
laboratory of respiratory infection viruses at the Institut Pasteur on 29 January 2020 in
France. This will allow the identification of antigenic structures involved in the immune
response and the development of serological diagnostic tests.
Many questions are being asked about this new virus and the infection it causes, including
questions about the transition from animal to human occur, the beginning of viral circulation
in humans, the period of contagiousness, the percentage of asymptomatic and pauci-symptomatic
forms. Serological studies can provide answers to these questions. There is no serological
test for SARS-COV-2 yet, but the laboratory of respiratory infection viruses at the Institut
Pasteur is working on its development.
This study proposes to carry out a collection of samples taken from subjects who travelled to
China before the epidemic outbreak or suspected of being infected with SARS-CoV-2.
As soon as it is available, serology will be performed on the collected samples.
Other: Human Biological samples
Blood samples for serological tests
Other: Human Biological samples
Blood samples, saliva, nasopharyngeal swab for serological tests
Inclusion Criteria:
- Affiliated with or benefiting from a Social Security system
- State of health compatible with a blood sample as defined in the protocol
Exclusion Criteria:
- Person benefiting from a legal protection measure or unable to express informed
consent to participation
- Have had an infectious episode and/or respiratory signs in the 14 days prior to the
scheduled visit (CORSER 1 and 2a, 2b)
- Have been in contact with a confirmed case of SARS-CoV-2 infection within 14 days
prior to the date of the visit.(CORSER 1 and 2a, 2b)
CHU Amiens-Picardie
Amiens, France
EHPAD Villa Concorde
Asnieres sur seine, France
CHU François Mitterand
Dijon, France
Centre Hospitalier Départemental de Vendée
La Roche-sur-Yon, France
CHU Limoges
Limoges, France
Hôpital de la Croix Rousse
Lyon, France
EHPAD Les Etangs
Mennecy, France
CHRU de Nancy
Nancy, France
Hôpitaux de Brabois
Nancy, France
CHR Orléans
Orléans, France
Institut Mutualiste
Paris, France
Centre Médical de l'Institut Pasteur
Paris, France
Institut Pasteur
Paris, France
EHPAD Villa Lecourbe
Paris, France
Hôpital la Pitié Salpetrière
Paris, France
CHU Poitiers
Poitiers, France
Hôpital Pontchaillou
Rennes, France
CHU Saint-Etienne
Saint-Étienne, France
CHRU de Strasbourg
Strasbourg, France
CH de Tourcoing
Tourcoing, France
Hôpital Bretonneau
Tours, France
Bruno HOEN, Pr, Principal Investigator
Institut Pasteur